Your browser doesn't support javascript.
loading
DPP-4 inhibitor linagliptin ameliorates imiquimod-induced psoriasis-like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF-κB inflammatory pathway.
Shao, Zhulin; Li, Xiaohong; Xu, Xiangjin; Chen, Pin.
Afiliação
  • Shao Z; Department of Endocrinology, 900 Hospital of the Joint Logistics Team, Fuzong Clinical Medical College of Fujian Medical University, Fujian, Fuzhou, China.
  • Li X; Department of Endocrinology, 900 Hospital of the Joint Logistics Team, Fuzong Clinical Medical College of Fujian Medical University, Fujian, Fuzhou, China.
  • Xu X; Department of Endocrinology, 900 Hospital of the Joint Logistics Team, Fuzong Clinical Medical College of Fujian Medical University, Fujian, Fuzhou, China.
  • Chen P; Department of Endocrinology, 900 Hospital of the Joint Logistics Team, Fuzong Clinical Medical College of Fujian Medical University, Fujian, Fuzhou, China.
Drug Dev Res ; 83(6): 1373-1382, 2022 09.
Article em En | MEDLINE | ID: mdl-35749612
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Linagliptina Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Linagliptina Idioma: En Ano de publicação: 2022 Tipo de documento: Article